TY - JOUR AU - Hoffstetter, Rene AU - Riquelme, Ismael AU - Andana, Alejandra AU - Ili, Carmen G. AU - Buchegger, Kurt AU - Vargas, HernĂ¡n AU - Brebi, Priscilla AU - Roa, Juan Carlos PY - 2017 TI - Evaluation of DNA methylation in promoter regions of SFRP4 and ZAR1 in urine and plasma of women with cervical lesions JF - Translational Cancer Research; Vol 6, No 1 (February 27, 2017): Translational Cancer Research (Focused Issue: Advances on Clinical Immunotherapy) Y2 - 2017 KW - N2 - Background: Aberrant DNA hypermethylation in tumor suppressor genes is a common feature in cervical cancer (CC). This abnormal hypermethylation could be used as potential biomarkers for detecting CC in non-invasive samples such as urine and plasma. Methods: This study aimed to evaluate in urine and plasma the methylation status of two genes previously found hypermethylated in CC ( ZAR1 and SFRP4 ) and assesses their diagnostic value. Thus, DNA methylation was measured in 171 paired samples of urine and plasma taken from women with non-lesions [60], low-grade squamous intraepithelial lesions (L-SIL) [40], high-grade squamous intraepithelial lesions (H-SIL) [40] and cervical squamous cell carcinoma (SCC) [31] by quantitative methylation-specific PCR (QMSP). Results: In urine, a significant difference was observed for methylation levels of SFRP4 between cancer group and all the other groups (P ZAR1 . The ROC analysis in urine showed an AUC of 0.633 for both genes, with a specificity of 83.3% and a sensitivity of 45.16%. In plasma, there were no significant differences of DNA methylation levels either for ZAR1 or SFRP4 genes between the studied groups; however, an AUC of 0.6333 was obtained with a sensitivity of 93.55%. Conclusions: Hypermethylation of SFRP4 promoter region in urine could be used as CC biomarker within a panel of methylated genes. UR - https://tcr.amegroups.org/article/view/11960